Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire · Sep 8, 2026
BlackRock Inc. Makes New $40.55 Million Investment in Atea Pharmaceuticals, Inc. $AVIRDefense World · Sep 2, 2026
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 12, 2026
Atea Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 12, 2026Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.56 | -$0.41 | Beat |
| May 12, 2026 | -$0.60 | -$0.57 | Beat |
| Mar 5, 2026 | -$0.49 | -$0.57 | Miss |
| Nov 12, 2025 | -$0.46 | -$0.53 | Miss |
| Aug 7, 2025 | -$0.46 | -$0.44 | Beat |
| May 12, 2025 | -$0.56 | -$0.40 | Beat |